DOCSLIB.ORG

Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B–Containing Lipoprotein and HDL in Type 2 Diabetes a Potential Mechanism to Lower Plasma Triglycerides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B–Containing Lipoprotein and HDL in Type 2 Diabetes a Potential Mechanism to Lower Plasma Triglycerides Pathophysiology/Complications ORIGINAL ARTICLE Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B–Containing Lipoprotein and HDL in Type 2 Diabetes A potential mechanism to lower plasma triglycerides 1 GEESJE M. DALLINGA-THIE, PHD ON BEHALF OF THE DIABETES ATORVASTATIN ypertriglyceridemia, low levels of 2 INGRID I.L. BERK-PLANKEN, MD, PHD LIPID INTERVENTION (DALI) STUDY HDL cholesterol, and preponder- 2 AART H. BOOTSMA, MD, PHD GROUP* 2,3,4 ance of small, dense LDL particles ANS ANSEN PHD H H J , are risk factors for cardiovascular disease (CVD) (1,2) and are part of the athero- genic lipoprotein profile often present in patients with type 2 diabetes. The initia- tion of the atherogenic lipoprotein profile OBJECTIVE — Apolipoprotein (apo)C-III is a constituent of HDL (HDL apoC-III) and of remains to be established. Kissebah et al. apoB-containing lipoproteins (LpB:C-III). It slows the clearance of triglyceride-rich lipoproteins (TRLs) by inhibition of the activity of the enzyme lipoprotein lipase (LPL) and by interference (3) demonstrated that in type 2 diabetic with lipoprotein binding to cell-surface receptors. Elevated plasma LpB:C-III is an independent subjects, apolipoprotein (apo)B and risk factor for cardiovascular disease. We studied the effect of atorvastatin on plasma LpB:C-III VLDL triglyceride secretion was en- and HDL apoC-III. hanced, but did not necessarily lead to hypertriglyceridemia. In Pima Indians, RESEARCH DESIGN AND METHODS — We studied the effect of 30 weeks’ treatment hypertriglyceridemia may develop with- with 10 and 80 mg atorvastatin on plasma apoC-III levels in a randomized, double-blind, out increased triglyceride production due placebo-controlled trial involving 217 patients with type 2 diabetes and fasting plasma triglyc- to a decreased VLDL triglyceride clear- erides between 1.5 and 6.0 mmol/l. ance capacity (4). Wilson et al. (5) RESULTS — Baseline levels of total plasma apoC-III, HDL apoC-III, and LpB:C-III were showed that in a pedigree with type 2 41.5 Ϯ 10.0, 17.7 Ϯ 5.5, and 23.8 Ϯ 7.7 mg/l, respectively. Plasma apoC-III was strongly diabetes, hypertriglyceridemia only de- correlated with plasma triglycerides (r ϭ 0.74, P Ͻ 0.001). Atorvastatin 10- and 80-mg treat- veloped in subjects with decreased li- ment significantly decreased plasma apoC-III (atorvastatin 10 mg, 21%, and 80 mg, 27%), HDL poprotein lipase (LPL) activity due to a apoC-III (atorvastatin 10 mg, 22%, and 80 mg, 28%) and LpB:C-III (atorvastatin 10 mg, 23%, genetic defect. Therefore, delayed effi- and 80 mg, 28%; all P Ͻ 0.001). The decrease in plasma apoC-III, mainly in LpB:C-III, strongly ciency of clearance of triglyceride-rich li- correlated with a decrease in triglycerides (atorvastatin 10 mg, r ϭ 0.70, and 80 mg, r ϭ 0.78; poproteins (TRLs) may be a major cause Ͻ P 0.001). Atorvastatin treatment also leads to a reduction in the HDL apoC-III–to–HDL of the development of hypertriglyceride- cholesterol and HDL apoC-III–to–apoA-I ratios, indicating a change in the number of apoC-III mia in type 2 diabetes. The clearance of per HDL particle (atorvastatin 10 mg, Ϫ21%, and 80 mg, Ϫ31%; P Ͻ 0.001). TRLs in situ is dependent on the presence CONCLUSIONS — Atorvastatin treatment resulted in a significant dose-dependent reduc- of stimulatory and inhibitory factors. In tion in plasma apoC-III, HDL apoC-III, and LpB:C-III levels in patients with type 2 diabetes. vitro studies (6,7) have implicated apoC- These data indicate a potentially important antiatherogenic effect of statin treatment and may III as a noncompetitive inhibitor of LPL. explain (part of) the triglyceride-lowering effect of atorvastatin. ApoC-III may also attenuate the clearance of TRL remnants by interfering with the Diabetes Care 27:1358–1364, 2004 hepatic lipoprotein receptors (8,9). Stud- ies with genetically modified animals sup- ●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●● port the hypothesis that apoC-III affects the metabolism of TRLs. Transgenic mice 1 From the Department of Internal Medicine, University Medical Center Utrecht, Utrecht, the Netherlands; overexpressing the human apoC-III gene the 2Department of Internal Medicine, Erasmus Medical Center, Rotterdam, the Netherlands; the 3Depart- ment of Biochemistry, Erasmus Medical Center, Rotterdam, the Netherlands; and the 4Department of developed severe hypertriglyceridemia Clinical Chemistry, Erasmus Medical Center, Rotterdam, the Netherlands. (10) due to impaired catabolism of TRLs Address correspondence and reprint requests to Dr. G.M. Dallinga-Thie, Laboratory of Vascular Medicine (11,12), whereas mice lacking apoC-III and Metabolism, Room Bd 277, Department of Internal Medicine, Erasmus MC, Dr Molewaterplein 40, 3015 showed a very efficient clearance of VLDL GD Rotterdam, P.O. Box 2040, 3000CA Rotterdam, Netherlands. E-mail: [email protected]. Received for publication 7 October 2003 and accepted in revised form 16 March 2004. particles and had enhanced selective up- *An appendix at the end of this article lists the members of the DALI study group. take of VLDL cholesterol esters (13,14). Abbreviations: apo, apolipoprotein; CVD, cardiovascular disease; DALI, Diabetes Atorvastatin Lipid In healthy control subjects and hy- Intervention; HDL apoC-III, apoC-III in HDL; LpB:C-III, apoC-III in apoB-containing lipoprotein; LPL, perlipidemic patients, plasma triglycer- lipoprotein lipase; TRL, triglyceride-rich lipoprotein. A table elsewhere in this issue shows conventional and Syste`me International (SI) units and conversion ides and apoC-III concentration are factors for many substances. strongly correlated (15,16). Patients with © 2004 by the American Diabetes Association. elevated levels of plasma triglycerides had 1358 DIABETES CARE, VOLUME 27, NUMBER 6, JUNE 2004 Dallinga-Thie and Associates Table 1 —Baseline characteristics RESEARCH DESIGN AND METHODS — This study is part of the Atorvastatin Diabetes Atorvastatin Lipid Intervention (DALI) study. DALI is a randomized, Placebo 10 mg 80 mg double-blind, placebo-controlled, multi- n 71 72 70 center study conducted in the Nether- Male sex (%) 46.5 61.1 54.3 lands (30). Briefly, 217 patients, aged Ϯ Ϯ Ϯ 45–75 years, with type 2 diabetes for at Age (years) 59 8608608 Յ BMI (kg/m2) 32.2 Ϯ 6.1 30.0 Ϯ 3.8 30.4 Ϯ 4.5 least 1 year and an HbA1c 10%, partic- Fasting glucose (mmol/l) 10.53 Ϯ 3.66 10.52 Ϯ 3007 10.66 Ϯ 2.98 ipating in the DALI study were random- Ϯ Ϯ Ϯ ized to placebo, atorvastatin 10 mg, or HbA1c (%) 8.34 1.14 8.26 1.16 8.42 1.12 LPL (units/l) 126.8 Ϯ 52.4 131.9 Ϯ 52.9 129.5 Ϯ 46.4 atorvastatin 80 mg for 30 weeks to eval- Triglycerides (mmol/l) 2.63 Ϯ 0.91 2.55 Ϯ 0.88 2.84 Ϯ 1.12 uate the effect of treatment on lipid me- Total cholesterol (mmol/l) 6.04 Ϯ 0.81 5.90 Ϯ 0.90 6.02 Ϯ 0.90 tabolism. Type 2 diabetes was defined LDL cholesterol (mmol/l) 3.80 Ϯ 0.79 3.70 Ϯ 0.91 3.74 Ϯ 0.90 according to the American Diabetes Asso- HDL cholesterol (mmol/l) 1.05 Ϯ 0.21 1.05 Ϯ 0.26 1.04 Ϯ 0.24 ciation classification (33). Inclusion crite- ApoA-I (g/l) 1.41 Ϯ 0.19 1.39 Ϯ 0.20 1.40 Ϯ 0.21 ria were fasting plasma triglycerides ApoB (mg/100 ml) 1.28 Ϯ 0.19 1.22 Ϯ 0.20 1.24 Ϯ 0.24 between 1.5 and 6.0 mmol/l, total choles- terol between 4.0 and 8.0 mmol/l, and no Data are means Ϯ SD. history of CVD. Patients were recruited in Leiden, Rotterdam, and Utrecht. The eth- increased plasma levels of apoC-III, with a ments aimed at affecting apoC-III levels ics committees of the participating centers fourfold larger proportion of apoC-III areofgreatinterest.Statinsmaylowerplas- approved the study protocol, and all pro- present in VLDL-sized particles com- ma apoC-III. In 27 patients with primary cedures followed were in accordance with pared with normolipidemic individuals hypertriglyceridemia, 20–40 mg atorva- institutional guidelines. The primary end (17–20). In contrast, patients with a ge- statin for 4 weeks reduced plasma apoC- point was the percentage decrease in netic deficiency in apoC-III had low levels III by 18–30% (28). In 305 patients with plasma triglyceride levels after atorvasta- of plasma VLDL because of an enhanced primary hypercholesterolemia (29), both tin treatment, as described elsewhere fractional catabolic rate and a rapid con- atorvastatin and pravastatin reduced LpB: (30). The secondary end point was version of VLDL into intermediate- C-III by ϳ30%. In contrast, in patients changes in specialized lipid parameters. density lipoprotein and LDL (21). ApoC- with coronary artery bypass graft, lova- Written informed consent was obtained III in apoB-containing lipoproteins (LpB: statin therapy lowered the concentrations from all subjects. C-III) mainly reflects apoC-III present on of apoB-containing lipoproteins (LDL), triglyceride-rich particles and may di- but not plasma apoC-III or LpB:C-III Analytical methods rectly affect LPL activity and receptor (19). Blood samples were drawn after a fasting binding. HDL functions as a sink for sur- Atorvastatin is a powerful HMG-CoA period of 12 h at baseline and after 30 plus apoC-III in plasma, and a high level reductase inhibitor proven to effectively weeks’ treatment at the end of the study. may indirectly affect triglyceride clear- reduce total plasma cholesterol and tri- Plasma was prepared by immediate cen- ance (22). trifugation, and samples were stored at glyceride levels.
Load more

Recommended publications
  • Polymorphisms in APOA1 and LPL Genes Are Statistically Independently Associated with Fasting TG in Men with CAD
    European Journal of Human Genetics (2005) 13, 445–451 & 2005 Nature Publishing Group All rights reserved 1018-4813/05 $30.00 www.nature.com/ejhg ARTICLE Polymorphisms in APOA1 and LPL genes are statistically independently associated with fasting TG in men with CAD Olga W Souverein*,1, J Wouter Jukema2, S Matthijs Boekholdt3, Aeilko H Zwinderman1 and Michael WT Tanck1 1Department of Clinical Epidemiology and Biostatistics, Academic Medical Center, Amsterdam, The Netherlands; 2Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands; 3Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands The objective of this paper was to identify the single nucleotide polymorphisms (SNPs) that show unshared effects on plasma triglyceride (TG) levels and to investigate whether these SNPs show statistically independent effects on plasma TG levels. In total, 59 polymorphisms in 20 genes involved in lipid metabolism were investigated. Polymorphisms were selected for a multivariate ANOVA model if they showed an univariate association with TG (after adjustment for HDL-C and LDL-C) in more than 50% of bootstrap samples that were made from the original data. The multivariate model included 512 men with coronary artery disease from the REGRESS study who were completely genotyped for eight polymorphisms selected in the univariate procedure (ie, APOA1 G(À75)A, ABCA1 C(À477)T, ABCA1 G1051A, APOC3 T3206G, APOE Arg158Cys, LIPC C(À514)T, LPL Asn291Ser and LPL Ser447Stop). The gene variants APOA1 G(À75)A (P ¼ 0.04) and LPL Asn291Ser (P ¼ 0.03) were significantly associated with plasma TG levels in this multivariate analysis. The eight polymorphisms explained 8.9% of the variation in plasma TG levels.
    [Show full text]
  • The Crucial Roles of Apolipoproteins E and C-III in Apob Lipoprotein Metabolism in Normolipidemia and Hypertriglyceridemia
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Harvard University - DASH The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Sacks, Frank M. 2015. “The Crucial Roles of Apolipoproteins E and C-III in apoB Lipoprotein Metabolism in Normolipidemia and Hypertriglyceridemia.” Current Opinion in Lipidology 26 (1) (February): 56–63. doi:10.1097/mol.0000000000000146. Published Version doi:10.1097/MOL.0000000000000146 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:30203554 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Open Access Policy Articles, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#OAP HHS Public Access Author manuscript Author Manuscript Author ManuscriptCurr Opin Author Manuscript Lipidol. Author Author Manuscript manuscript; available in PMC 2016 February 01. Published in final edited form as: Curr Opin Lipidol. 2015 February ; 26(1): 56–63. doi:10.1097/MOL.0000000000000146. The crucial roles of apolipoproteins E and C-III in apoB lipoprotein metabolism in normolipidemia and hypertriglyceridemia Frank M. Sacks Department of Nutrition, Harvard School of Public Health, Boston, Massachusetts, USA Abstract Purpose of review—To describe the roles of apolipoprotein C-III (apoC-III) and apoE in VLDL and LDL metabolism Recent findings—ApoC-III can block clearance from the circulation of apolipoprotein B (apoB) lipoproteins, whereas apoE mediates their clearance.
    [Show full text]
  • Lrp1 Modulators
    Last updated on February 14, 2021 Cognitive Vitality Reports® are reports written by neuroscientists at the Alzheimer’s Drug Discovery Foundation (ADDF). These scientific reports include analysis of drugs, drugs-in- development, drug targets, supplements, nutraceuticals, food/drink, non-pharmacologic interventions, and risk factors. Neuroscientists evaluate the potential benefit (or harm) for brain health, as well as for age-related health concerns that can affect brain health (e.g., cardiovascular diseases, cancers, diabetes/metabolic syndrome). In addition, these reports include evaluation of safety data, from clinical trials if available, and from preclinical models. Lrp1 Modulators Evidence Summary Lrp1 has a variety of essential functions, mediated by a diverse array of ligands. Therapeutics will need to target specific interactions. Neuroprotective Benefit: Lrp1-mediated interactions promote Aβ clearance, Aβ generation, tau propagation, brain glucose utilization, and brain lipid homeostasis. The therapeutic effect will depend on the interaction targeted. Aging and related health concerns: Lrp1 plays mixed roles in cardiovascular diseases and cancer, dependent on context. Lrp1 is dysregulated in metabolic disease, which may contribute to insulin resistance. Safety: Broad-spectrum Lrp1 modulators are untenable therapeutics due to the high potential for extensive side effects. Therapies that target a specific Lrp1-ligand interaction are expected to have a better therapeutic profile. 1 Last updated on February 14, 2021 Availability: Research use Dose: N/A Chemical formula: N/A S16 is in clinical trials MW: N/A Half life: N/A BBB: Angiopep is a peptide that facilitates BBB penetrance by interacting with Lrp1 Clinical trials: S16, an Lrp1 Observational studies: sLrp1 levels are agonist was tested in healthy altered in Alzheimer’s disease, volunteers (n=10) in a Phase 1 cardiovascular disease, and metabolic study.
    [Show full text]
  • Association Between the APOA2 Rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels Through BMI
    biomedicines Article Association between the APOA2 rs3813627 Single Nucleotide Polymorphism and HDL and APOA1 Levels Through BMI Hatim Boughanem 1 , Borja Bandera-Merchán 2, Pablo Hernández-Alonso 2,3,4 , Noelia Moreno-Morales 5, Francisco José Tinahones 2,3, José Lozano 6 , Sonsoles Morcillo 2,3,* and Manuel Macias-Gonzalez 2,3,* 1 Instituto de Investigación Biomédica de Málaga (IBIMA), Facultad de Ciencias, Universidad de Málaga, 29010 Málaga, Spain; [email protected] 2 Unidad de Gestión Clínica de Endocrinología y Nutrición del Hospital Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, 29010 Málaga, Spain; [email protected] (B.B.-M.); [email protected] (P.H.-A.); [email protected] (F.J.T.) 3 Centro de Investigación Biomédica en Red de Fisiopatología de la Obesidad y la Nutrición, CIBERObn, 28029 Madrid, Spain 4 Human Nutrition Unit, Faculty of Medicine and Health Sciences, Sant Joan Hospital, Institut d’Investigació Sanitària Pere Virgili, Rovira i Virgili University, 43201 Reus, Spain 5 Department of Physiotherapy, School of Health Sciences, University of Malaga-Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain; [email protected] 6 Departamento de Bioquímica y Biología Molecular, Facultad de Ciencias, Universidad de Málaga, 29010 Málaga, Spain; [email protected] * Correspondence: [email protected] (S.M.); [email protected] (M.M.-G.); Tel.: +34-951-032-648 (S.M. & M.M.-G.); Fax: +34-27-951-924-651 (S.M. & M.M.-G.) Received: 18 February 2020; Accepted: 25 February 2020; Published: 27 February 2020 Abstract: Background: The interaction between obesity and genetic traits on high density lipoprotein (HDL) levels has been extensively studied.
    [Show full text]
  • Apolipoproteins and Their Association with Cardiometabolic Risk
    Nutr Hosp. 2015;32(6):2674-2683 ISSN 0212-1611 • CODEN NUHOEQ S.V.R. 318 Original / Síndrome metabólico Apolipoproteins and their association with cardiometabolic risk biomarkers in adolescents Mellina Neyla de Lima Albuquerque1, Alcides da Silva Diniz1 and Ilma Kruze Grande de Arruda1 1Department of Nutrition. Federal University of Pernambuco, Recife, Brazil. Abstract APOLIPOPROTEÍNAS Y SU ASOCIACIÓN CON BIOMARCADORES DE RIESGO Introduction: the apoB/apo A-I ratio has been reported CARDIOMETABÓLICO EN ADOLESCENTES as an important predictor of cardiovascular risk, being superior to lipids, lipoproteins and conventional lipid ra- tios. Resumen Objective: to investigate the association between apo- Introducción: la razón apo B/apo A-I sigue siendo lipoproteins A-I and B, and the apolipoprotein B/apoli- reportada como un predictor importante de riesgo car- poprotein A-I ratio and cardiometabolic risk variables in diovascular, superior a lípidos, lipoproteínas y razones adolescents. lipídicas convencionales. Objetivo: investigar la asocia- Methods: this was a cross-sectional study including ción entre las apolipoproteínas A-I y B y la razón apoli- 104 adolescents of public schools in Recife during the poproteína B/apolipoproteína A-I con variables de riesgo months of March/April, 2013. Sociodemographic, an- cardiometabólico en adolescentes. thropometric, clinical and biochemical variables were Métodos: estudio de corte transversal que incluye a analysed. The apolipoproteins were analysed via Immu- 104 adolescentes de escuelas públicas de
    [Show full text]
  • Apolipoprotein A4 Gene (APOA4) (Chromosome 11/Haplotypes/Intron Loss/Coronary Artery Disease/Apoal-APOC3 Deficiency) Sotirios K
    Proc. Natl. Acad. Sci. USA Vol. 83, pp. 8457-8461, November 1986 Biochemistry Structure, evolution, and polymorphisms of the human apolipoprotein A4 gene (APOA4) (chromosome 11/haplotypes/intron loss/coronary artery disease/APOAl-APOC3 deficiency) SOTIRios K. KARATHANASIS*t, PETER OETTGEN*t, ISSAM A. HADDAD*t, AND STYLIANOS E. ANTONARAKISt *Laboratory of Molecular and Cellular Cardiology, Department of Cardiology, Children's Hospital and tDepartment of Pediatrics, Harvard Medical School, Boston, MA 02115; and tDepartment of Pediatrics, Genetics Unit, The Johns Hopkins University, School of Medicine, Baltimore, MD 21205 Communicated by Donald S. Fredrickson, July 11, 1986 ABSTRACT The genes coding for three proteins of the APOC3 deficiency and premature coronary artery disease plasma lipid transport system-apolipoproteins Al (APOAI), (13-15), hypertriglyceridemia (16), and hypoalphalipopro- C3 (APOC3), and A4 (APOA4)-are closely linked and teinemia (17). tandemly organized on the long arm ofhuman chromosome 11. In this report the nucleotide sequence of the human In this study the human APOA4 gene has been isolated and APOA4 gene has been determined. The results suggest that characterized. In contrast to APOAl and APOC3 genes, which the APOAI, APOC3, and APOA4 genes were derived from a contain three introns, the APOA4 gene contains only two. An common evolutionary ancestor and indicate that during intron interrupting the 5' noncoding region of the APOA1 and evolution the APOA4 gene lost one of its ancestral introns. APOC3 mRNAs is absent from the corresponding position of Screening of the APOA4 gene region for polymorphisms the APOA4 mRNA. However, similar to APOAI and APOC3 showed that two different Xba I restriction endonuclease genes, the introns of the APOA4 gene separate nucleotide sites are polymorphic in Mediterranean and Northern Euro- sequences coding for the signal peptide and the amphipathic pean populations.
    [Show full text]
  • Low-Density Lipoprotein Receptor–Dependent and Low-Density Lipoprotein Receptor–Independent Mechanisms of Cyclosporin A–Induced Dyslipidemia
    Original Research Low-Density Lipoprotein Receptor–Dependent and Low-Density Lipoprotein Receptor–Independent Mechanisms of Cyclosporin A–Induced Dyslipidemia Maaike Kockx, Elias Glaros, Betty Kan, Theodore W. Ng, Jimmy F.P. Berbée, Virginie Deswaerte, Diana Nawara, Carmel Quinn, Kerry-Anne Rye, Wendy Jessup, Patrick C.N. Rensen, Peter J. Meikle, Leonard Kritharides Objective—Cyclosporin A (CsA) is an immunosuppressant commonly used to prevent organ rejection but is associated with hyperlipidemia and an increased risk of cardiovascular disease. Although studies suggest that CsA-induced hyperlipidemia is mediated by inhibition of low-density lipoprotein receptor (LDLr)–mediated lipoprotein clearance, the data supporting this are inconclusive. We therefore sought to investigate the role of the LDLr in CsA-induced hyperlipidemia by using Ldlr-knockout mice (Ldlr−/−). Approach and Results—Ldlr−/− and wild-type (wt) C57Bl/6 mice were treated with 20 mg/kg per d CsA for 4 weeks. On a chow diet, CsA caused marked dyslipidemia in Ldlr−/− but not in wt mice. Hyperlipidemia was characterized by a prominent increase in plasma very low–density lipoprotein and intermediate-density lipoprotein/LDL with unchanged plasma high-density lipoprotein levels, thus mimicking the dyslipidemic profile observed in humans. Analysis of specific lipid species by liquid chromatography–tandem mass spectrometry suggested a predominant effect of CsA on increased very low–density lipoprotein–IDL/LDL lipoprotein number rather than composition. Mechanistic studies indicated that CsA did not alter hepatic lipoprotein production but did inhibit plasma clearance and hepatic uptake of [14C]cholesteryl oleate and glycerol tri[3H]oleate-double-labeled very low–density lipoprotein–like particles.
    [Show full text]
  • Apolipoprotein B
    Laboratory Procedure Manual Analyte: Apolipoprotein B Matrix: Serum Method: Turbidimetric Assay on Roche Cobas® 6000 Method No.: Revised: As performed by: University of Minnesota – Advanced Research Diagnostics Laboratory (ARDL) Contact: Dr. Anthony Killeen, MD, PhD University of Minnesota Medical Center Fairview-University Medical Center University Campus Minneapolis, Minnesota Important Information for Users University of Minnesota – Advanced Research Diagnostics Laboratory (ARDL) periodically refines these laboratory methods. It is the responsibility of the user to contact the person listed on the title page of each write-up before using the analytical method to find out whether any changes have been made and what revisions, if any, have been incorporated. Apolipoprotein B NHANES 2015-2016 Public Release Data Set Information This document details the Lab Protocol for testing the items listed in the following table: Data File Name Variable Name SAS Label LBXAPB Apolipoprotein B (mg/dL) APOB_I LBDAPBSI Apolipoprotein B (g/L) 2 of 20 Apolipoprotein B NHANES 2015-2016 1. SUMMARY OF TEST PRINCIPLE AND CLINICAL RELEVANCE A. Clinical Relevance Apolipoproteins are the protein constituents of the lipoproteins. Apolipoprotein B (Apo B) is the major protein component of low-density lipoprotein (LDL). About one-third of the LDL particles provide cholesterol to peripheral cells. The other two-thirds are metabolized by the liver. LDL-uptake in all of these cells occurs via LDL receptors. Apo B levels increase in hypercholesterolemia, pregnancy, LDL receptor defects, bile obstruction and nephrotic syndrome. Apo B levels decrease in liver disease, sepsis and estrogen administration. The combined measurement of apolipoprotein A-1 (Apo A1, present in HDL) and Apo B and the calculation of the Apo B:Apo A1 ratio can reflect a lipid metabolism disorder and the risk of developing atherosclerosis or coronary heart disease.
    [Show full text]
  • A Case of Ezetimibe-Effective Hypercholesterolemia with a Novel Heterozygous Variant in ABCG5
    2020, 67 (11), 1099-1105 Original A case of ezetimibe-effective hypercholesterolemia with a novel heterozygous variant in ABCG5 Yujiro Nakano1), Chikara Komiya1), Hitomi Shimizu2), 3), Hiroyuki Mishima3), Kumiko Shiba1), Kazutaka Tsujimoto1), Kenji Ikeda1), Kenichi Kashimada4), Sumito Dateki2), Koh-ichiro Yoshiura3), Yoshihiro Ogawa5) and Tetsuya Yamada1) 1) Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan 2) Department of Pediatrics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaski 852-8501, Japan 3) Department of Human Genetics, Graduate School of Biomedical Sciences, Nagasaki University, Nagasaki 852-8501, Japan 4) Department of Pediatrics and Developmental Biology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo 113-8519, Japan 5) Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka 812-8582, Japan Abstract. Sitosterolemia is caused by homozygous or compound heterozygous gene mutations in either ATP-binding cassette subfamily G member 5 (ABCG5) or 8 (ABCG8). Since ABCG5 and ABCG8 play pivotal roles in the excretion of neutral sterols into feces and bile, patients with sitosterolemia present elevated levels of serum plant sterols and in some cases also hypercholesterolemia. A 48-year-old woman was referred to our hospital for hypercholesterolemia. She had been misdiagnosed with familial hypercholesterolemia at the age of 20 and her serum low-density lipoprotein cholesterol (LDL-C) levels had remained about 200–300 mg/dL at the former clinic. Although the treatment of hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors was ineffective, her serum LDL-C levels were normalized by ezetimibe, a cholesterol transporter inhibitor.
    [Show full text]
  • Common Genetic Variations Involved in the Inter-Individual Variability Of
    nutrients Review Common Genetic Variations Involved in the Inter-Individual Variability of Circulating Cholesterol Concentrations in Response to Diets: A Narrative Review of Recent Evidence Mohammad M. H. Abdullah 1 , Itzel Vazquez-Vidal 2, David J. Baer 3, James D. House 4 , Peter J. H. Jones 5 and Charles Desmarchelier 6,* 1 Department of Food Science and Nutrition, Kuwait University, Kuwait City 10002, Kuwait; [email protected] 2 Richardson Centre for Functional Foods & Nutraceuticals, University of Manitoba, Winnipeg, MB R3T 6C5, Canada; [email protected] 3 United States Department of Agriculture, Agricultural Research Service, Beltsville, MD 20705, USA; [email protected] 4 Department of Food and Human Nutritional Sciences, University of Manitoba, Winnipeg, MB R3T 2N2, Canada; [email protected] 5 Nutritional Fundamentals for Health, Vaudreuil-Dorion, QC J7V 5V5, Canada; [email protected] 6 Aix Marseille University, INRAE, INSERM, C2VN, 13005 Marseille, France * Correspondence: [email protected] Abstract: The number of nutrigenetic studies dedicated to the identification of single nucleotide Citation: Abdullah, M.M.H.; polymorphisms (SNPs) modulating blood lipid profiles in response to dietary interventions has Vazquez-Vidal, I.; Baer, D.J.; House, increased considerably over the last decade. However, the robustness of the evidence-based sci- J.D.; Jones, P.J.H.; Desmarchelier, C. ence supporting the area remains to be evaluated. The objective of this review was to present Common Genetic Variations Involved recent findings concerning the effects of interactions between SNPs in genes involved in cholesterol in the Inter-Individual Variability of metabolism and transport, and dietary intakes or interventions on circulating cholesterol concen- Circulating Cholesterol trations, which are causally involved in cardiovascular diseases and established biomarkers of Concentrations in Response to Diets: cardiovascular health.
    [Show full text]
  • Apoa4 Antibody Cat
    ApoA4 Antibody Cat. No.: 6269 Western blot analysis of ApoA4 in chicken small intestine tissue lysate with ApoA4 antibody at 1 μg/mL Specifications HOST SPECIES: Rabbit SPECIES REACTIVITY: Chicken, Human ApoA4 antibody was raised against a 20 amino acid synthetic peptide near the carboxy terminus of chicken ApoA4. IMMUNOGEN: The immunogen is located within the last 50 amino acids of ApoA4. TESTED APPLICATIONS: ELISA, WB ApoA4 antibody can be used for detection of ApoA4 by Western blot at 1 μg/mL. APPLICATIONS: Antibody validated: Western Blot in chicken samples. All other applications and species not yet tested. POSITIVE CONTROL: 1) Chicken Small Intestine Lysate Properties PURIFICATION: ApoA4 Antibody is affinity chromatography purified via peptide column. CLONALITY: Polyclonal ISOTYPE: IgG September 24, 2021 1 https://www.prosci-inc.com/apoa4-antibody-6269.html CONJUGATE: Unconjugated PHYSICAL STATE: Liquid BUFFER: ApoA4 Antibody is supplied in PBS containing 0.02% sodium azide. CONCENTRATION: 1 mg/mL ApoA4 antibody can be stored at 4˚C for three months and -20˚C, stable for up to one STORAGE CONDITIONS: year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. Additional Info OFFICIAL SYMBOL: APOA4 ALTERNATE NAMES: ApoA4 Antibody: Apolipoprotein A-IV, Apolipoprotein A4, Apo-AIV ACCESSION NO.: NP_990269 PROTEIN GI NO.: 71773110 GENE ID: 337 USER NOTE: Optimal dilutions for each application to be determined by the researcher. Background and References ApoA4 Antibody: Apolipoprotein A4 (also known as ApoA-IV) is a plasma protein that is O- linked glycoprotein after proteolytic processing.
    [Show full text]
  • Cholesterol and Saturated Fat Intake Determine the Effect Of
    article September 2006 ⅐ Vol. 8 ⅐ No. 9 Cholesterol and saturated fat intake determine the effect of polymorphisms at ABCG5/ABCG8 genes on lipid levels in children Enrique Viturro, PhD1, Manuel de Oya, PhD, MD1, Miguel A. Lasuncio´n, PhD2, Lydia Gorgojo, PhD, MD3, Jose´ M. Martı´n Moreno, PhD, MD3, Mercedes Benavente, PhD1, Beatriz Cano, PhD1, and Carmen Garces, PhD1 Purpose: Analysis of mutations in genes of the cholesterol metabolic pathway has not completely explained the interindividual variability of blood cholesterol concentrations attributed to gene–nutrient interactions. Thus, we analyzed polymorphisms in the ABCG5 and ABCG8 genes, involved in the regulation of intestinal cholesterol absorption, with special interest in a potential interaction with diet to determine lipid levels. Methods: The polymorphisms ABCG5 C1950G (Gln604Glu) and ABCG8 C1895T (Ala640Val) were determined by polymerase chain reaction and restriction analysis in 1227 healthy school children, aged 6 to 8 years. Results: No significant differences were found in blood lipid levels between subjects with different genotypes of the two analyzed polymorphisms. However, important differences appeared when separating subjects by their different lipid intake. The presence of the ABCG8 C1895T and ABCG5 C1950G polymorphisms was associated with different plasma total cholesterol, low-density lipoprotein cholesterol complex, and apolipoprotein B levels only in low-cholesterol consumers (significantly for the C1895T polymorphism), and among children within the lower tertile of saturated fat intake (significantly for the C1950G polymorphism). Conclusion: Polymorphisms at the half-transporter ABCG5 and ABCG8 genes affect blood cholesterol concentrations in prepubertal children by influencing dietary respon- siveness. This highly significant gene–nutrient interaction could explain the great individual differences in the plasma lipid response to cholesterol and fat intake.
    [Show full text]